Capecitabine

Indications & Dose:

Stage III colon cancer, adjuvant following surgery (monotherapy) l

• BY MOUTH

Adult: 1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability—consult product literature

Stage III colon cancer, adjuvant following surgery (combination therapy) l

• BY MOUTH

Adult: 0.8–1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability—consult product literature

Metastatic colorectal cancer (monotherapy) l

• BY MOUTH

Adult: 1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature

Metastatic colorectal cancer (combination therapy) l

• BY MOUTH

Adult: 0.8–1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature

Advanced gastric cancer (first-line treatment in combination with a platinum based regimen) l

• BY MOUTH

Adult: 0.8–1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, alternatively 625 mg/m2 twice daily given continuously, adjust dose according to tolerability— consult product literature

Locally advanced or metastatic breast cancer (second-line treatment as monotherapy after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated) | Locally advanced or metastatic breast cancer (second-line treatment, in combination with docetaxel, where previous therapy included an anthracycline) l

• BY MOUTH

Adult: 1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature 

Contraindications:

 Severe renal or hepatic impairment. Hypersensitivity to fluoropyrimidines or fluorouracil. Dihydropyrimidine dehydrogenase deficiency. Severe leucopenia, neutropenia or thrombocytopenia. Pregnancy, lactation.

Side Effects:

Dizziness, fatigue, GI upset, handfoot syndrome, alopecia, skin or nail reactions, pyrexia, weakness, limb pain, headache, neurological disorders, oedema, blood dyscrasia, altered blood chemistry, weight loss, dehydration, dyspnoea, lacrimation, appetite loss, epistaxi pain, anorexia, depression.

• Report any adverse reaction to CSM.

Cautions:

Precautions:

Interaction:

Drugs
Sorivudine, brivudine, coumarin anticoagulants, phenytoin, folinic acid, antacids, allopurinol, interferon alfa-2a.

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Mild to moderate hepatic impairment, moderate renal impairment. History of cardiac disease, hypocalcaemia, hypercalcaemia, nervous system disease, diabetes, diarrhoea, abdominal pain, nausea, stomatitis, handfoot syndrome. Elderly. 

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: